{
    "nct_id": "NCT06445062",
    "official_title": "A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors",
    "inclusion_criteria": "All Patients (unless otherwise noted):\n\n* â‰¥ 18 years of age\n* ECOG PS is 0 to 1\n* Adequate organ function as outlined by the study\n* Pathologically or cytologically documented pancreatic carcinoma or poorly differentiated pancreatic carcinoma with metastatic disease or RAS-mutated, histologically or cytologically confirmed colorectal adenocarcinoma with documented unresectable or metastatic disease (Subprotocol A, B, and C)\n* Presence of RAS G12D mutation (Subprotocol D, E, F)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "All Patients:\n\n* Primary central nervous system (CNS) tumors\n* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs\n* Major surgery within 28 days of first dose\n\nOther inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}